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IGF-IR cooperates with ERα 
to inhibit breast cancer cell 
aggressiveness by regulating the 
expression and localisation of ECM 
molecules
Nikolaos A. Afratis1,2,*, Panagiotis Bouris1,*, Spyros S. Skandalis1, Hinke A. Multhaupt2, 
John R. Couchman2, Achilleas D. Theocharis1 & Nikos K. Karamanos1
IGF-IR is highly associated with the behaviour of breast cancer cells. In ERα-positive breast cancer, 
IGF-IR is present at high levels. In clinical practice, prolonged treatment with anti-estrogen agents 
results in resistance to the therapy with activation of alternative signaling pathways. Receptor 
Tyrosine Kinases, and especially IGF-IR, have crucial roles in these processes. Here, we report a nodal 
role of IGF-IR in the regulation of ERα-positive breast cancer cell aggressiveness and the regulation 
of expression levels of several extracellular matrix molecules. In particular, activation of IGF-IR, but 
not EGFR, in MCF-7 breast cancer cells results in the reduction of specific matrix metalloproteinases 
and their inhibitors. In contrast, IGF-IR inhibition leads to the depletion by endocytosis of syndecan-4. 
Global important changes in cell adhesion receptors, which include integrins and syndecan-4 triggered 
by IGF-IR inhibition, regulate adhesion and invasion. Cell function assays that were performed in MCF-7 
cells as well as their ERα-suppressed counterparts indicate that ER status is a major determinant of 
IGF-IR regulatory role on cell adhesion and invasion. The strong inhibitory role of IGF-IR on breast 
cancer cells aggressiveness for which E2-ERα signaling pathway seems to be essential, highlights IGF-IR 
as a major molecular target for novel therapeutic strategies.
Breast cancer is the most common type of cancer among women1. Steroid hormones and their receptors are of 
high significance in breast cancer since many tumours are hormone-dependent and they are often correlated 
with high mortality rates2. Estrogen receptors (ERs) are significant regulators of many vital processes of breast 
cancer cells. Due to their significance in breast cancer biology, ER status classifies breast tumors in two categories: 
ER-positive (luminal A and B) and ER-negative (normal-like, HER-2 enriched, basal and claudin-low)3. ERs exist 
in two main forms: ERα and ERβ . However, due to the fact that two-thirds of breast tumors are ERα positive, 
most studies evaluate the role of this particular receptor in disease progression.
IGF-IR is a receptor tyrosine kinase of high significance in breast cancer. Its activation plays pivotal roles in 
cell proliferation and differentiation, as well as in cell-cell adhesion. Several studies indicate a correlation between 
ERα and IGF-IR activities4,5. More specifically, in a non-genomic process, E2 induces the interactions of mem-
brane ERs with several proteins, such as growth factor-dependent kinases or adaptor proteins. A portion of ERs 
has the ability to localize at the membrane in multiprotein complexes. Thus their activation by E2 triggers the ini-
tiation of several downstream signaling molecules, such as c-Src, the regulatory subunit of PI-3K (p85), MAPK, 
AKT, p21ras and PKC6. This response pathway is very rapid compared to the genomic pathway. In addition, the 
non-genomic pathway may affect several cell functions including proliferation, survival and apoptosis7. It has 
been reported that the binding of E2 to membrane ERs triggers the rapid activation of growth factor receptors 
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such as IGF-IR and EGFR and their downstream signaling pathways8–12. This cross-talk between growth factor 
receptors and ERs may also regulate breast cancer cell growth13 as well as the expression of extracellular matrix 
(ECM) macromolecules14.
ECM is a highly dynamic and functional network, which consists of a variety of molecules including collagens, 
glycoproteins, matrix proteinases and proteoglycans (PGs). This network creates the scaffold for tissue and organ 
establishment. Changes in the expression of ECM molecules as well as compositional alterations among them 
markedly affect the assembly of ECM and its ability to regulate many crucial cellular functions15. ECM remode-
ling significantly contributes to cancer progression and development. Matrix metalloproteinases (MMPs) com-
prise a large family of zinc-binding endopeptidases, which together with their endogenous inhibitors (TIMPs), 
are highly involved in these processes. Cell migration, invasion, metastasis and angiogenesis are four integral 
processes in tumor development that are dependent on the surrounding microenvironment. Through their pro-
teolytic action, MMPs degrade a variety of ECM and cell adhesion molecules, thus modulating cell–cell and 
cell–ECM interactions16,17.
PGs and especially cell-associated heparan sulfate PGs (HSPGs), such as syndecans and glypicans, have impor-
tant regulatory roles in breast cancer cell behaviour. Alterations in HSPGs expression levels during malignancies 
associate with disease progression18. For example, elevated syndecan-1 levels, particularly in the tumour stroma, 
indicate poor prognosis19–21. HSPGs interact with other cell surface receptors, such as growth factor tyrosine 
kinase receptors and integrins. In recent studies, it has been shown that syndecan-1 regulates VE-cadherin and 
VEGF-mediated activation of α ν β 3 integrin and, via IGF-IR, induce cell proliferation in metastatic breast cancer 
cells22–25. Moreover, syndecan-2 and syndecan-4 expression levels and their cross talk with EGFR and IGF-IR 
signaling pathways have been investigated. In ERα -positive breast cancer cells, expression levels of syndecan-2 
are controlled through the EGFR signaling pathway, in contrast to syndecan-4 where the expression is regulated 
by IGF-IR signaling. The down-regulated levels of syndecan-2 and - 4 seem to be associated with higher migratory 
ability of breast cancer cells14,26.
The goal of our study was to investigate the role of IGF-IR in the aggressiveness of ERα -positive breast cancer 
cells. We evaluated the effect of IGF-R and its crosstalk with ERα and EGFR on critical cell properties as well as 
on the expression and/or localisation of certain syndecans, MMPs and TIMPs in breast cancer cells. Moreover, we 
evaluated whether the modified levels of syndecan-4 caused by IGF-IR depletion affects breast cancer cell behav-
iour. Finally, in order to investigate the significance of ERα on breast cancer and the importance of the synergistic 
actions of IGF-IR and ERα , cell function assays on MCF-7 (ERα -positive) and MCF-7/SP10+ (ERα -suppressed) 
cells were evaluated.
Results
IGF-IR activation down-regulates the gene expression levels of specific MMPs/TIMPs. To study 
the importance of matrix effectors in ERα -positive breast cancer cell behavior, we first examined the effect of 
ERα /IGF-IR/EGFR cross-talk on the gene expression of certain MMPs and TIMPs in MCF-7 cells. Treatment 
with the specific IGF-IR inhibitor, AG1024, revealed a slight down-regulation (ca 20–30%) of MT1-MMP expres-
sion, whereas no significant effect was observed for MMP-9, TIMP-1, and TIMP-2 (Fig. 1). Incubation with 
E2 also resulted in a similar slight down-regulation of MT1-MMP, MMP-9, and TIMP-1 compared to control 
cells. Activation of IGF-IR by IGF with concurrent EGFR inhibition in E2-treated cells resulted in a significant 
down-regulation (ca 40–60%) of all proteolytic enzymes and TIMPs examined (i.e. MT1-MMP, MMP-9, TIMP-1, 
and TIMP-2) (Fig. 1). On the other hand, no significant alterations were observed when EGFR was activated by 
EGF except for TIMP-2, which exhibited a strong down-regulation. These data indicated that IGF-IR, one of the 
major receptor tyrosine kinases (RTKs) in ERα -positive MCF-7 breast cancer cells, may be a key regulator of the 
proteolytic potential of MCF-7 cells since IGF-IR activation down-regulated MMPs/TIMPs expression that may 
limit tumour cell aggressiveness.
IGF-IR inhibition down-regulates cell surface expression levels of syndecan-4. The well-described 
importance of cell membrane HSPGs in cell functional properties (such as adhesion, invasion, proliferation) as 
well as in cancer progression prompted us to further investigate their roles, in particular those of syndecans, in 
breast cancer cell behavior. Previous studies in our lab have demonstrated that specific RTKs (IGF-IR and EGFR) 
are key mediators for the expression of syndecans in MCF-7 cells14. In the present study, these observations were 
further investigated by performing FACS analysis and immunofluorescence microscopy. Specifically, FACS analysis 
showed no difference in cell surface levels of syndecan-1 after treatment with either the EGFR or IGF-IR inhibitors 
(AG1478 or AG1024, respectively) in the absence or presence (16 h) of E2 (Fig. 2A). Simultaneous treatment with 
both inhibitors in the presence of E2, led to a reduction of surface levels of a pool of syndecan-1, which was evident 
at 24 h (Fig. 2A). In contrast, syndecan-4 cell surface levels were significantly reduced (ca 50%) after treatment with 
IGF-IR inhibitor (AG1024) either in the absence or presence (16 h) of E2. The same results were obtained when cells 
were treated with both RTK inhibitors in the absence or presence (24 h) of E2 (Fig. 2B). These results indicated that 
IGF-IR inhibition significantly reduced cell surface syndecan-4 in an E2-independent manner, but had a little or no 
effect on syndecan-1. Immunofluorescence analysis showed that inhibition of either IGF-IR alone or both receptors 
in the presence of E2 (i.e. E2 + AG1478 + AG1024) resulted in different localization and cellular distribution of 
syndecan-1 and syndecan-4 characterized by a decrease of their cell surface expression, especially in the case of 
syndecan-4, together with stronger cytoplasmic staining (Fig. 2C and D). Moreover, treatment of cells with IGF 
or EGF in the presence of EGFR and IGF-IR inhibitors, respectively, resulted in restoration of cell surface levels of 
syndecan-1 (Fig. 2C). Taken together, these results indicated that IGF-IR regulates mainly syndecan-4, and to a lesser 
extent syndecan-1, expression and localization in ERα -positive MCF-7 breast cancer cells. Co-immunoprecipitation 
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experiments revealed the presence of syndecan-4/IGF-IR complexes in syndecan-4-overexpressing cells (Fig. 2E), 
further indicating the cooperation of IGF-IR with syndecan-4 to accomplish cellular functions.
IGF-IR inhibition triggers syndecan-4 endocytosis. To further investigate the reduction of cell surface 
levels of syndecan-4 after 16 h of IGF-IR inhibition, FACS analyses were performed at early time points (0, 2, 4, 6 
and 8 h). The results revealed that the depletion of syndecan-4 from the cell surface was evident even at 2 h after 
IGF-IR inhibition (Fig. 3A), which gradually increased to approx. 50% by 16 h (Fig. 2B). To examine whether the 
observed reduction of cell surface syndecan-4 levels after the IGF-IR inhibition was due to proteoglycan endocy-
tosis, the same experiment was performed at 15 °C. Under these conditions, the cell surface levels of syndecan-4 
remained unaltered during the first 6 h after treatment with AG1024, while a slight reduction was observed after 
8 h (Fig. 3B). These results indicated that the significant reduction of cell surface levels of syndecan-4 following 
inhibition of IGF-IR is most likely due to syndecan-4 endocytosis. To exclude the possibility that the reduction 
of cell surface syndecan-4 resulted from syndecan-4 shedding, FACS analysis was performed in the presence of 
the metalloproteinases inhibitor GM6001. The results revealed that cell surface levels of syndecan-4 were reduced 
after IGF-IR inhibition regardless of the presence or absence of GM6001, demonstrating that the observed reduc-
tion was due to syndecan-4 endocytosis rather than shedding (Fig. 3C).
Integrin-based adhesive ability of ERα+ breast cancer cells, but not the invasiveness, is reg-
ulated by IGF-IR inhibition. Given the crucial role of syndecan-4 in cell adhesion and migration27,28, we 
further investigated the impact of the observed syndecan-4 endocytosis induced by IGF-IR inhibition on cell 
functional properties. We first examined the effects of IGF-IR inhibition on an array of integrin dimer expression 
since several studies have demonstrated the cooperation of syndecan-4 with integrins29–31. Cell surface expres-
sion of four “RGD-binding” heterodimers α 5β 1, α vβ 3, α vβ 5, and α vβ 6 was significantly down-regulated in 
AG1024-treated MCF-7 cells (approximately 80%, 60%, 80%, and 80%, respectively) compared to those of con-
trol cells (Fig. 4A). These results indicated that IGF-IR inhibition down-regulated important adhesion elements 
Figure 1. Evaluation of gene expression levels of MMPs and TIMPs after treatment with specific tyrosine 
kinase inhibitors and E2 in MCF-7 breast cancer cells. The effect of IGF-IR or EGFR inhibition on the 
constitutive and the E2-mediated gene expression of (A) MT1-MMP, (B) MMP-9, (C) TIMP-1, and (D) TIMP-2 
in MCF-7 breast cancer cells. The mRNA levels were assessed by Real Time PCR analysis. Cells were pre-treated 
with inhibitor of EGFR (AG1478, 1 μ Μ ) or IGF-IR (AG1024, 1 μ Μ ) for 30 min, followed by the introduction of 
E2 (10 nM), EGF (5 ng/mL) and IGF (15 ng/mL) where indicated. Total incubation time was 16 h. Statistically 
significant differences compared with control or E2-treated cells are shown with *(p < 0.05), **(p < 0.01), 
***(p < 0.001) or ##(p < 0.01), ###(p < 0.001), respectively.
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combined with syndecan-4 internalisation. Subunits of laminin-binding integrins (α 3, α 6, β 4) were expressed at 
low levels. However, IGF-IR inhibition led to significant up-regulation of expression levels of α 2 and β 1 integrin 
subunits, which can combine as a well-known collagen binding receptor (Fig. 4B). As a consequence, IGF-IR 
inhibition alone did not affect cell adhesion to collagen I, but it significantly increased (ca 50%) cell adhesion 
of E2-treated cells compared to untreated cells, indicating a possible cross-talk between integrins, IGF-IR and 
E2-ERα signaling pathways (Fig. 4C). Moreover, functional blocking of the α 2β 1 integrin heterodimer by the 
specific P1E6 antibody resulted in the reduction of MCF-7 cells adherence on type I collagen. This inhibitory 
effect was further enhanced following inhibition of IGF-IR. Notably, IGF-IR inhibition leads to significant 
down-regulation of major adhesive molecules, like syndecan-4 and integrins, except for the collagen binding α 2 
Figure 2. Investigation of IGF-IR and EGFR inhibition on syndecan expression levels and localisation. 
Evaluation of (A) syndecan-1 and (B) syndecan-4 cell surface protein levels by flow cytometry. The experiments 
were performed following treatments with EGFR and IGF-IR inhibitors, in the presence or the absence of 
E2. Immunocytochemical localisation of (C) syndecan-1 and (D) syndecan-4 after treatment with EGFR and 
IGF-IR inhibitors, in the presence or the absence of E2. Bars = 25 μ m. (E) Immunoprecipitation of syndecan-4 
with IGF-IR from MCF-7 cell lysates.
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and β 1 integrin subunits. The over-expression of α 2 and β 1 subunits in relation with the significant reduction of 
the adhesion ability of the MCF-7 cells by blocking their action (Fig. 4D) highlights α 2β 1 as a critical mediator 
of cell adhesion. On the other hand, IGF-IR inhibition significantly induced (ca 30%) the invasive potential of 
ERα -positive MCF-7 cells into collagen I gels in an E2-independent manner (Fig. 4E) and the invasiveness of 
these cells is not dependent on the actions of MMPs (Fig. 4F). Taken together, these results indicated that the 
cross-talk of IGF-IR and E2-ERα pathways affect cell adhesion but not invasion, the latter being affected by 
IGF-IR alone.
ERα is essential for the protective actions of IGF-IR in breast cancer cells. To further investigate 
the role of IGF-IR and its cross-talk with E2-ERα signaling pathway in the functional properties of ERα -positive 
breast cancer cells, the same experimental protocols were applied to ERα -knock down MCF-7 breast cancer 
cells (designated MCF-7/SP10+ cells) previously established in our laboratory32. Notably, these cells exhibited 
Figure 3. Loss of syndecan-4 on ERα+ breast cancer cells resulting from IGF-IR inhibition is reduced at 
low temperature but not after MMP inhibition. Time course of IGF-IR inhibition on cell surface syndecan-4 
levels, in the presence or absence of E2, at 37 °C (A) or 15 °C (B). Control MCF-7 cultures were not exposed to 
AG1024 IGF-IR inhibitor. Lowering temperature to slow down internalisation reduced the loss of syndecan-4. 
(C) Similar FACS analysis of MCF-7 cells untreated or treated with IGF-IR inhibitor and/or EGF inhibitor in the 
presence or absence of E2 and the GM6001 general MMP inhibitor. Syndecan-4 levels were decreased despite 
the presence of sheddase inhibitor.
www.nature.com/scientificreports/
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significantly lower mRNA and protein levels of IGF-IR and syndecan-4, while those of EGFR were significantly 
increased compared to the parental MCF-7 cells (Fig. 5A). Importantly, the strong stimulatory effect of IGF-IR 
inhibition on cell adhesion to collagen I in E2-treated ERα -positive MCF-7 cells was lost in ERα -knock down 
cells (MCF-7/SP10+ cells) revealing that ERα is essential for the suppressive action of IGF-IR in cell adhesion 
(Fig. 5B). Moreover, in ERα -knock down  cells the α 2 integrin subunit is not essential for the adherence of 
these cells compared to parental MCF-7 (Fig. 5C). Moreover, the stimulatory effect of IGF-IR inhibition on 
the invasiveness of ERα -positive MCF-7 cells was lost when ERα was knocked down (MCF-7/SP10+ cells) 
suggesting that ERα is also necessary for the suppressive action of IGF-IR on cell invasion (Fig. 5D). In contrast 
to MCF-7 cells, for  ERα-knock down  cells, MMPs seem to be crucial for their invasiveness (Fig. 5E). Taken 
together, these results demonstrate that IGF-IR reduces the aggressiveness of ERα -positive breast cancer cells and 
Figure 4. The role of IGF-IR on cell functions of MCF-7 breast cancer cells. (A,B) Evaluation of MCF-7 cell 
adhesion to substrates coated with integrin-specific antibodies. Treatment with IGF-IR inhibitor markedly 
reduced adhesion to all four substrates comprised of antibodies to “RGD-binding” integrins. In contrast, 
adhesion to antibodies against the collagen-binding α 2 subunit was increased. Data in A normalised to α 5β 1  
antibody adhesion in the absence of inhibitor. (C) The effect of IGF-IR on both the constitutive and the  
E2-mediated cell adhesion to type I collagen substrates by MCF-7 breast cancer cells. Adhesion was increased 
by E2 treatment, particularly where IGF-IR was inhibited. (D) The blocking of α 2 integrin reduced the 
adhesion ability on type I collagen substrates. The inhibition with both AG1024 and anti-α 2 antibody led to 
the enhancement of this effect. (E) The effect of IGF-IR inhibition on type I collagen gel invasion by MCF-7 
breast cancer cells, in the presence or absence of E2. Cells were incubated with AG1024 (inhibitor of IGF-IR) 
(1 μ Μ ) for 30 min, followed by the introduction of E2 (10 nm), where indicated. Total incubation time was 
24 h. Invasion was increased following IGF-IR inhibition. (F) Treatment of MCF-7 cell with GM6001 (MMPs 
inhibitor) had no effect on invasion ability of these cells. Statistically significant differences compared with 
control or E2-treated cells are shown as *(p < 0.05), **(p < 0.01), ***(p < 0.001) or #(p < 0.05), ##(p < 0.01), 
respectively.
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suggest that the protective role of IGF-IR and/or its cross-talk with ERα in these cells is lost in ERα -suppressed 
breast cancer cells.
Discussion
Estrogens are pivotal in the growth of both normal and neoplastic mammary tissues and mediate most of their 
actions via estrogen receptors. Both genomic and non-genomic actions of E2 play crucial roles in E2-induced 
cancer cell proliferation and survival33. Since the majority of breast tumors are ER-dependent, blockade of E2 
synthesis with aromatase inhibitors or antagonism of its action with anti-estrogens, represent first-line treat-
ments for patients with ER-positive breast cancer. However, the majority of ERα -positive tumors, even if initially 
responsive to treatment with anti-estrogenic reagents such as tamoxifen, will eventually develop resistance to this 
treatment34. Membrane ERs may play a significant role in this resistance inducing the activation of key cell mem-
brane receptors, such as IGF-IR and EGFR35,36. Both IGF-IR and EGFR are receptor tyrosine kinases with similar 
intracellular signaling pathways, including the activation of MAPKs or PI3K. Insulin-like growth factor-1 (IGF-I) 
is an important mediator of cellular proliferation and is strongly linked to the progression of a number of human 
Figure 5. Loss of ERα strongly augments aggressiveness of MCF-7 breast cancer cells. (A) Confirmation 
of loss of ERα in MCF-7 SP10+ cells, which also led to almost complete loss of IGF-IR and syndecan-4 but to 
increased levels of EGFR. Gene expression levels were measured by Real-Time PCR and protein expression 
levels were measured by western blotting analysis. (B) The effect of IGF-IR on cell adhesion to collagen I 
substrate in the presence or absence of E2 of MCF-7 SP10+ breast cancer cells. (C) The blocking of α 2β 1  
integrin had no effect on adhesion to collagen I of MCF-7 SP10+ cells. (D) The effect of IGF-IR on both the 
constitutive and the E2-mediated cell invasion on MCF-7 SP10+ breast cancer cells, respectively. Cell invasion 
was assessed by collagen type I assay. Cancer cells were incubated with the inhibitor of IGF-IR (AG1024, 1 μ Μ )  
for 30 min, followed by the introduction of E2 (10 nM), where it was necessary. Total incubation time was 
24 h. (E) The inhibition of MMPs, in the presence or the absence of IGF-IR inhibitor, led to suppression of 
invasiveness of MCF-7 SP10+ cells. Statistically significant differences compared with control or E2-treated 
cells are symbolized with *(p < 0.05), **(p < 0.01), ***(p < 0.001).
www.nature.com/scientificreports/
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cancers, including breast cancer. In this study, we provide data that support the significant role of IGF-IR in the 
aggressiveness of breast cancer cells. The significance of this receptor in cancer homeostasis is known. Specifically, 
the inhibition of the IGF-I/IGF-IR pathway results in reduced growth of breast cancer cell lines37. Moreover, 
IGF-IR is expressed at high levels in breast cancer, while its expression is positively correlated with estrogen recep-
tor levels38. On the other hand, the EGFR is involved in various aspects of cell growth, survival, differentiation, 
migration, and invasion39,40. EGFR is often present in excessive amounts in human breast cancers. Moreover, 
several studies imply a cooperation of membrane ERs with IGF-IR and EGFR. More specifically, the mechanism 
of this cooperation is a linear activation of IGF-IR by ERs which in turn activates several MMPs. MMPs shed 
heparin binding-epidermal growth factor (HB-EGF) that binds the receptor resulting in the phosphorylation of 
EGFR, and downstream signaling cascades that include the MAP kinases41–44.
MMPs are key players in tumor progression because of their ability to remodel ECM and cleave/activate 
membrane-bound and pericellular growth factors, ECM proteins, and cytokines that stimulate cancer cell prolif-
eration, migration and invasion45–47. A plethora of MMPs are over-expressed in breast tumors, though different 
MMPs mediate specific cell functions. For example, MMP-9 and MT1-MMP regulate breast cancer cell invasion 
and migration48–51. We have demonstrated previously that the action of E2 regulates gene expression and activ-
ity of MMPs52,53. In addition, the expression and the activity of MMPs/TIMPs may also be modulated by either 
IGF-IR or EGFR. EGF induces the expression of MMP-9 in SKB3 breast cancer cells54 while the introduction of 
exogenous IGF-I enhances MMP activity in MCF-7 breast cancer cells55. However, it is not yet known whether the 
interplay between these signaling axes may regulate the expression of MMPs/TIMPs in breast cancer56.
Here, we examined the importance of ECM in the cross-talk between ERs/IGF-IR/EGFR in breast cancer cell 
aggressiveness. In the case of MMPs, the membrane associated MT1-MMP was down-regulated in the presence 
of IGF-IR inhibitor, but in the additional presence of E2, which results in the activation of ERα , MT1-MMP 
returned to control levels. On the other hand, EGFR seems to act the other way around, with significant 
down-regulation of MT1-MMP levels in the presence of EGFR inhibitor or activation of IGF-IR with IGF. In 
the same system, MMP-9 as well as TIMP-1 and TIMP-2 have similar expression patterns to MT1-MMP. These 
data indicate that IGF-IR activation regulates critical proteolytic enzymes by balancing the expression levels of 
the proteases (MMPs) and their endogenous inhibitors (TIMPs). Overall, these data indicate that IGF-IR action 
drastically lowers the aggressive potential of breast cancer cells.
On the other hand, syndecans are molecules that are highly involved in cell adhesion and migration. In 
pathological conditions, increased syndecan shedding by proteinases like MMPs has been observed. Syndecan-4 
promotes cell adhesion, in contrast to syndecan-1, which is increased during malignancies and promotes the 
aggressiveness of cancer cells20. After FACS analyses of cell surface syndecans levels in the presence or absence of 
RTKs (IGF-IR and EGFR) inhibitors, a significant down-regulation of syndecan-4, after treatment with IGF-IR 
inhibitor, in an E2-independent manner was observed. In the case of syndecan-1, only slight effects on protein 
levels after inhibition of IGF-R pathway were observed. Inhibition of IGF-IR resulted in a different localisation 
and cellular distribution of syndecan-4 and, to a lesser extent, syndecan-1. Syndecan-4 levels on the cell surface 
were decreased while stronger cytoplasmic staining was observed, consistent with the observed internalization 
of the proteoglycan. Immunoprecipitation of syndecan-4 identified IGF-IR in the same complex, indicating a 
potentially important synergistic role of IGF-IR on syndecan-4-mediated cell functions. It has been demonstrated 
previously that syndecan-1 and IGF-IR can be observed together in complexes23.
Syndecan-4 and integrins are key molecules in cell adhesion and migration on MCF-7 breast cancer cells 
and syndecan-4 reduced levels after inhibition of IGF-IR pathway could affect breast cancer cell behaviour. A 
significant reduction of the adhesive capacity caused by lower cell surface expression levels of α 5β 1, α ν β 3, α ν β 5 
and α ν β 6 integrins after inhibition of IGF-IR signaling pathway was observed. This result suggested that the 
inhibition of IGF-IR and the resulting endocytosis of syndecan-4 down-regulate the expression levels and/or 
stabilisation of other adhesive molecules like integrins from the cell surface, with the exception of the collagen 
binding α 2β 1 integrin, where a significant up-regulation was observed. The blocking of the α 2β 1 integrin het-
erodimer revealed that the up-regulated adhesion ability of MCF-7 cell on collagen type I substrate is mediated 
by α 2β 1 integrin. These data verify that adhesion of AG1024-treated MCF-7 cells was abolished on fibronectin 
substrates, but not collagen I because of the up-regulation of α 2β 1 integrin57. It is likely that larger molecular 
complexes containing syndecan-4, IGF-IR and integrins may exist. It is well known that integrins and syndecan-4 
are concentrated in focal adhesions, for example27,29 and in the case of syndecan-1 the coupling with IGF-IR is 
responsible for integrin heterodimer activation23,58,59. It is therefore plausible that the inhibition of IGF-IR, with 
concomitant internalisation of syndecan-4, decreases the integrin(s) responsible for the adhesion of MCF-7 cells 
to fibronectin and laminin substrates, but not collagen type I, owing to α 2 integrin overexpression. Moreover, 
decreased adhesion was associated with up-regulation of the invasive index after the inhibition of IGF-IR, in an 
E2- and MMP-independent manner, suggesting that the loss of adhesive molecules caused by IGF-IR inhibition 
has a dramatic effect on cell invasion-promoting ability of the MCF-7 cells.
The current data demonstrate that the co-operation of IGF-IR and E2-ERα signaling pathways is significant 
for breast cancer cell behaviour in promoting a non-aggressive phenotype. To independently examine this, we 
compared MCF-7 (ERα -positive) and MCF-7/SP10+ (ERα -suppressed) cell lines. Notably, MCF-7/SP10+ lack-
ing ERα, but also IGF-IR and syndecan-4 as a result of the loss of ERα are characterised by a more aggressive 
phenotype and higher levels of EGFR compared to the parental MCF-7 cells. The inductive role of IGF-IR on 
cell adhesion is highly correlated with the expression levels of ERα , because the loss of ERα and IGF-IR led to 
less adherent cells and a striking increase in invasiveness. Moreover, the co-ordinated loss of ERα and IGF-IR 
led to significant reduction of syndecan-4 expression levels. In conclusion, the functions of ERα -positive and 
ERα -negative mammary carcinoma cells are regulated by different mechanisms; in ERα -positive cells, the IGF-IR 
and the adhesive molecules, like syndecans and integrins, play crucial roles, whereas in ERα -negative cells the 
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MMPs mediate cancer cell invasion. These data underline the significant role of IGF-IR in the aggressiveness of 
breast cancer cells and correlate its action with ER status and syndecan-4 expression levels.
Methods
Chemicals, reagents and antibodies. Dulbecco’s modified eagles medium (DMEM), fetal bovine serum 
(FBS), sodium pyruvate, L-glutamine, penicillin, streptomycin, amphotericin B and gentamycin were all obtained 
from Biosera LTD (Courtabo euf Cedex, France). The cytostatic agent cytarabine, E2 the of EGFR inhibitor 
AG1478, the AG1024 inhibitor of IGF-IR, and EGF were also purchased from Sigma Chemical Co. (St Louis, MO, 
USA). IGF was purchased from R&D systems (Minneapolis, USA). All other chemicals used were of the best com-
mercially available grade. Antibodies used were mouse monoclonal anti-syndecan-4 (5G9; Santa Cruz), mouse 
monoclonal anti-syndecan-1 (B-A38; Abcam), mouse monoclonal anti-HA (Clone HA.11; Covance), rabbit pol-
yclonal against IGF-IRβ (D23H3; Cell signaling), rabbit polyclonal against ERα (HC-20, sc-534; Santa Cruz), 
rabbit polyclonal against ERβ (H-150, sc-8974; Santa Cruz) and mouse monoclonal to integrin alpha 2 + beta1 
[P1E6] (ab24697; Abcam).
Cell cultures. The MCF-7 (low metastatic, ERα -positive) breast cancer cell line was obtained from the 
American Type Culture Collection (ATCC) and routinely cultured as monolayers at 37 °C in a humidified atmos-
phere of 5% (v/v) CO2 and 95% air. MCF-7/SP10+ (ERα -suppressed cells) was previously described32. Breast cancer 
cells were cultured in DMEM supplemented with 10% (v/v) FBS, 1.0 mM sodium pyruvate, 2 mM L-glutamine and 
a cocktail of antimicrobial agents (0.8 μ g/mL puromycin, 100 IU/mL penicillin, 100 μ g/mL streptomycin, 10 μ g/mL 
gentamycin sulphate and 2.5 μ g/mL amphotericin B). Puromycin (0.8 μ g/mL) was included in the cultures of 
MCF-7/SP10+ cells. Cells were harvested by trypsinization with 0.05% (w/v) trypsin in PBS containing 0.02% 
(w/v) Na2EDTA. Breast cancer cells were grown in serum-containing medium up to 80% confluence and then was 
followed overnight incubation in serum-free culture medium. The pre-treatment with AG1024 was for 30 min 
and then were added the E2 and growth factors for 16 h. All experiments were conducted in serum-free condi-
tions. The transfection reagent for the performed experiments was the lipofectamine 2000 (Lipofectamine 2000, 
Invitrogen), which was used according to the manufacturer’s instructions.
RNA isolation and real time PCR analysis. Cells were harvested and total RNA samples were isolated 
after cell lysis using NucleoSpin® RNA II Kit (Macherey-Nagel, Duren, Germany). The amount of isolated RNA 
was quantified by measuring its absorbance at 260 nm.
Total RNA was reverse transcribed using the PrimeScript™ 1st strand cDNA synthesis kit (Takara Bio 
Inc., Japan) and KAPA TaqReadyMix DNA Polymerase (KAPABIOSYSTEMS). Real-time PCR analysis 
was conducted in 20 μ L reaction mixture, consisting of 10 μ L KAPA SYBR FAST Master Mix (2x) Universal 
(KAPABIOSYSTEMS) and 1 μ Μ of template cDNA. The amplification was performed utilizing Rotor Gene Q 
(Qiagen, USA). Standard curves were run in each optimized assay which produced a linear plot of threshold cycle 
(Ct) against log (dilution). The amount of each target was quantified based on the concentration of the standard 
curve and was presented as arbitrary units. The quantity of each target was normalized against the quantity of 
GAPDH. Genes of interest and utilized primers are presented in Supplementary Table S1.
Flow Cytometry. Cells were incubated with dissociation buffer (Invitrogen) and suspended in ice-cold PBS 
contains 1% FCS and stained with syndecan-1 (1:50) or syndecan-4 (1:50) antibodies for 30 min on ice. Then, the 
sample were washed three-times with FACS buffer and incubated with Alexa Flour-conjugated anti-mouse IgG 
for 30 min and analyzed on a FACSCalibur flow cytometer and the data were processed by using Cell Quest Pro 
v6.0 software (Becton Dickinson).
Confocal Microscopy. Cells were seeded onto coverslips in 24-well plate and incubated in DMEM + 10% 
FCS for 24 h before transfection. After transfection cells were incubated for 48 h and then fixed in 4% paraform-
aldehyde in PBS and permeabilised with 0.1% Triton X-100 for 10 min. Coverslips were incubated with 0.1 M 
NH4Cl for 20 min to quench free aldehydes and blocked with 5% normal goat serum for 30 min. Afterwards, cells 
were stained with primary antibodies overnight at 4 °C and followed by incubation with Alexa Fluor-conjugated 
antibodies for 1 h at room temperature. Cells were mounted in Prolong Gold mounting media (Invitrogen), ana-
lyzed by confocal laser-scanning microscope (LSM510 Meta, Carl Zeiss, Oberkochen, Germany) equipped with a 
63x/1.4 Plan-Apochromat oil immersion objectives and images processed using Zen Software.
Adhesion assays. For measurements of cell surface integrin levels wells were coated with mouse monoclonal 
antibodies against integrin extracellular domains (Chemicon- Millipore) QCM™ , ECM535). Monoclonal anti-
bodies against α 1, α 2, α 3, α 4, α 5, α V, α Vβ 3, β 1, β 2, β 3, β 4, β 6, α Vβ 5, α 5β 1 integrins and a goat anti-mouse 
IgG as negative control were immobilised. Cells were cultured for 24 h, in the presence or absence of the IGF-IR 
inhibitor (1 μ M AG1024). Cells were washed three times with a serum free medium and then suspended in serum 
free medium and 1.5 × 105 cells were placed in the wells. After 2 h incubation the cells were washed three times 
with serum free DMEM so that non-adherent cells were removed. Afterwards the attached cells were lysed and 
incubated with CyQUANT ™ GR Dye. Measurements were made on a fluorimeter (Infinite® , Tecan) with excita-
tion at 485 nm and emission at 530 nm.
In order to evaluate the adhesive potential of breast cancer cells the following adhesion protocol was con-
ducted as described previously60. Briefly, 40 μ g/ml of collagen type I in PBS and 0.1% BSA solution in serum 
free medium were prepared. 96-well plate coated for 12 h at 4 °C with collagen type I solution (30 μ g/ml). Then, 
the solution was removed and the plate was air-dried. Cancer cells were deprived of serum for 8 h prior to the 
adhesion assay and in the case of blocking with P1E6 antibody or anti-mouse IgG, a 30 min incubation before 
the beginning of the assay in final concentration of 20 μ g/mL for both antibodies was used. Then the cells were 
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detached with PBS-EDTA 1x, re-suspended with 0.1% BSA and seeded at a density of 2 × 104 cells/well. Cells 
were incubated for 30 min in order to be allowed to adhere to the surface. Non-adherent cells were removed with 
serum free medium and then cells were incubated with medium supplemented with 10% FBS for 4 h for recovery. 
After incubation period, Premix WST-1 (water-soluble tetrazolium salt) Cell Proliferation Assay System (Takara 
Bio Inc., Japan) was added at a ratio 1:10 and the absorbance at 450 nm was measured (reference wavelength at 
650 nm).
Western blotting and co-immunoprecipitation. Cells were lysed in a buffer containing 62.5 mM 
Tris-HCl pH 6.8, 2% sodium dodecyl sulfate (SDS), 10% glycerol, 5% β -mercaptoethanol and 0.001% bromo-
phenol blue. Cell lysates were separated on 10% SDS-PAGE, the proteins were electrophoretically transferred to 
membranes PVDF (Bio-Rad, USA) and blotted with the indicated antibodies as previously61.
For the co-immunoprecipitation experiments, the breast cancer cells were transfected with plasmid encod-
ing wild-type syndecan-461 and cultured for 24 h. Afterwards, the cells were lysed in ice cold buffer contain-
ing 20 mM HEPES pH 7.5, 150 mM NaCl, 1% Triton- X100, 2 mM EDTA, 1 mM PMSF and protease inhibitor 
cocktail. Lysates were sheared through a 25 G needle and mixed for 1 hour at 4 °C. Lysates were centrifuged at 
13,000 rpm for 5 min at 4 °C and supernatants were pre-adsorbed with protein G agarose beads (Sigma-Aldrich, 
St Louis, MO, USA) for 1 hour at 4 °C. The treated lysates were incubated overnight at 4 °C with anti-HA antibody 
and then incubated with protein G agarose beads for 1 hour at 4 °C. The beads were washed extensively followed 
by electrophoresis and immunoblotting analysis.
Collagen invasion assay. The invasive potential of breast cancer cells was evaluated using the collagen type I 
invasion assay, as described previously62. In brief, collagen type I solution with final concentration of 1 mg/ml 
was prepared by mixing the pre-cooled components: 4 volumes collagen type I (stock concentration 3 mg/ml), 
5 volumes of CMF-HBSS, 1 volume of DMEM (10x), 1 volume of 0.25 M NaHCO3, 2.65 volumes of DMEM and 
0.3 volumes of 1 M NaOH. The solution was gently mixed and added to one well of 12-well plate, spread homo-
geneously and allowed to gel in a humidified atmosphere of 10% CO2 at 37 °C for > 1 h. Breast cancer cells previ-
ously cultured in the presence or the absence of AG1024, E2, E2 + AG1024 and GM6001 in serum-free conditions 
for 16 h were seeded at a density of 6 × 104 cells per well on the top of the collagen gels. Cells were incubated in a 
humidified atmosphere of 10% CO2 at 37 °C and after 24 h digital images were obtained with a 10x objective. The 
calculation of cell invasion was as described by De Wever et al.62.
Statistical analysis. Reported values are expressed as mean  ±  standard deviation (SD) of experiments in 
triplicate. Statistically significant differences were evaluated using the analysis of variance (ANOVA) test and were 
considered statistically significant at the level of at least p ≤ 0.05. Statistical analysis and graphs were made using 
GraphPad Prism 6 (GraphPad Software).
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